Welcome to our dedicated page for Radnostix news (Ticker: INIS), a resource for investors and traders seeking the latest updates and insights on Radnostix stock.
International Isotopes Inc. (INIS), now known corporately as Radnostix, Inc., generates a steady flow of news related to its radioisotope, theranostics, and medical device activities. Headquartered in Idaho Falls, Idaho and incorporated in Texas, the company reports across several segments, including Theranostics Products, Calibration & Reference Products (formerly Nuclear Medicine Standards), Cobalt Products, Medical Devices, and a Fluorine Products segment associated with a proposed de-conversion facility.
News updates frequently cover quarterly and annual financial results, where the company discusses revenue trends, segment performance, gross profit, and the use of non-GAAP measures such as EBITDA and Adjusted EBITDA. These releases often highlight demand for generic sodium iodide I-131 radiopharmaceutical drug product, I-131 theranostic APIs, calibration and reference standards, and Cobalt-60 sealed source products, as well as the impact of global isotope supply conditions, such as shortages of Cobalt-57 and Gadolinium-153.
Investors and industry observers can also find corporate development news, including the legal name change to Radnostix, Inc., governance and bylaw changes, executive employment agreements, and board appointments. Operational news has included expansion of the company’s footprint in Idaho Falls through land acquisition and a new facility lease, which the company states is intended to support capacity growth across its segments.
Product and partnership announcements feature prominently as well. Examples include the creation of the PhanQual joint venture with Phantech Medical for pre-clinical calibration sources, the manufacturing joint venture with Alpha Nuclides to bring INIS and RadQual products into China via Radnostix China, and updates on the RadVent medical device lineup and EasyFill Automated Iodine Capsule System. For users tracking INIS, this news stream provides insight into segment dynamics, supply chain developments, facility expansion, and the company’s evolving theranostics and healthcare focus.
International Isotopes Inc. (OTCQB: INIS) reported its financial results for Q3 and nine months ended September 30, 2021. Q3 revenue decreased to $2,617,514 from $2,864,288 in 2020, while nine-month revenue slightly rose to $7,369,922 from $7,359,633. Operating expenses escalated over 14% due to increased depreciation from a new manufacturing facility. The company faced a net loss of $136,869 for Q3 and $919,408 for the nine months. Despite COVID-19 impacts, revenue for nuclear medicine products grew, attributed to the acquisition of RadQual LLC, which is expected to enhance future performance.
International Isotopes Inc. (OTCQB: INIS) reported a revenue of $2,759,896 for the second quarter of 2021, marking a 28% increase compared to $2,159,559 in Q2 2020. The revenue growth stemmed from higher sales in radiochemical products, cobalt products, and nuclear medicine standards, leading to an operating income of $14,722 versus a loss of $96,101 in the prior year. Notable increases included a 157% rise in cobalt product sales, aided by restored access to DOE resources, and a 14% growth in nuclear medicine sales.
International Isotopes Inc. (OTCQB: INIS) announced the acquisition of the remaining 75% of RadQual LLC, making it a wholly-owned subsidiary. This strategic move, executed through common shares, is valued at eight times projected earnings for the year, aiming to enhance shareholder equity and net profit margins. RadQual specializes in quality control products for nuclear medicine, particularly SPECT and PET imaging. This acquisition is expected to strengthen INIS's market position and potentially facilitate a listing on a major exchange in the future.
International Isotopes Inc. (OTCQB: INIS) reported a revenue of $1,992,512 for Q1 2021, marking a 15% decline from $2,335,786 in Q1 2020. The company faced a net loss of $601,152, up from $422,494 last year. The drop in revenue was primarily due to reduced sales in radiochemical and cobalt products, alongside higher operational costs. However, revenue from nuclear medicine products rose by 8%, attributed to recovering demand as COVID-19's impact diminishes. Management anticipates growth in radiochemical and cobalt segments moving forward.
International Isotopes (OTCQB: INIS) reported a net income of approximately $2.2 million for the year ended December 31, 2020, reversing a net loss of about $1.5 million in 2019. Total revenues rose to $9.3 million, a 5% increase from $8.9 million in 2019, driven by strong sales in the radiochemical and cobalt segments. The company achieved FDA approval for its sodium iodide I-131 product, resulting in a 43% revenue increase in the radiochemical sector. Significant improvements in liquidity were noted, with a 50% reduction in accounts payable.
International Isotopes Inc. (OTCQB: INIS) announced that its subsidiary RadQual has partnered with LEA for the distribution of calibration and reference sources in North America. LEA's products are globally recognized for their quality and are measured under the ISO 17025:2017 standard. This agreement will allow RadQual to import and distribute these high-value calibration sources across the U.S. and Canada, enhancing their product offerings in the nuclear medicine sector. This partnership is expected to provide customers with an alternative supply of high-quality products and improved service.
International Isotopes Inc. (OTCQB: INIS) reported financial results for Q2 and the first half of 2020. Q2 revenue rose by 1% to $2,159,559, but six-month revenue fell 4% to $4,495,345 due to COVID-19 impacts. Gross profit increased by 8% for Q2 and 1% for H1. Operating expenses rose by 8% in Q2 and 15% in H1, driven by staffing for new product development. Notable is a net income of $229,328 in Q2, up from a net loss of $1,157,194 in 2019. However, revenue from nuclear medicine products and radiological services decreased significantly due to the pandemic.